Tumour-derived GM-CSF promotes granulocyte ... · 72 the functional role of granulocytes and their mechanism of action in human mesothelioma 73 is not well understood. Studies in
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Tumour-derived GM-CSF promotes granulocyte immunosuppression in 1
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
1. Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and 510 implications for therapy. Nat Rev Cancer. 2017;17(8):475-88. 511 2. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. 512 Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin 513 Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. The Lancet. 514 2016;387(10026):1405-14. 515 3. Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. 516 Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting 517 CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra151. 518 4. Zauderer MG, Tsao AS, Dao T, Panageas KS, Lai WV, Rimner A, et al. A Randomized 519 Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality 520 Therapy for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2017. 521 5. Cornwall SM, Wikstrom M, Musk AW, Alvarez J, Nowak AK, Nelson DJ. Human 522 mesothelioma induces defects in dendritic cell numbers and antigen-processing function which 523 predict survival outcomes. Oncoimmunology. 2016;5(2):e1082028. 524 6. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Hegmans JP, 525 et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in 526 mesothelioma. Br J Cancer. 2010;103(5):629-41. 527 7. Chene AL, d'Almeida S, Blondy T, Tabiasco J, Deshayes S, Fonteneau JF, et al. Pleural 528 Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their 529 Differentiation into M2 Macrophages. J Thorac Oncol. 2016;11(10):1765-73. 530 8. Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, et al. The South West Area 531 Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating 532 novel markers of chemotherapy response and prognostication. Br J Cancer. 2015;112(7):1175-533 82. 534 9. Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, Ishimine A, et al. 535 CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural 536 mesothelioma after resection. Cancer immunology, immunotherapy : CII. 2010;59(10):1543-9. 537 10. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, et al. High blood 538 neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma 539 patients undergoing systemic therapy. Clinical cancer research : an official journal of the 540 American Association for Cancer Research. 2010;16(23):5805-13. 541 11. Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, et al. Factors associated 542 with survival in a large series of patients with malignant pleural mesothelioma in New South 543 Wales. British journal of cancer. 2014;111(9):1860-9. 544 12. Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, Sharma R. Inflammation-based 545 prognostic indices in malignant pleural mesothelioma. Journal of thoracic oncology : official 546 publication of the International Association for the Study of Lung Cancer. 2012;7(3):587-94. 547 13. Shaul ME, Levy L, Sun J, Mishalian I, Singhal S, Kapoor V, et al. Tumor-associated 548 neutrophils display a distinct N1 profile following TGFbeta modulation: A transcriptomics 549 analysis of pro- vs. antitumor TANs. Oncoimmunology. 2016;5(11):e1232221. 550 14. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, et al. In vivo loss of 551 expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for 552 susceptibility to arginine depletion. Clin Cancer Res. 2006;12(23):7126-31. 553
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
15. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, et al. Invariant NKT cells 554 modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum 555 amyloid A. Nat Immunol. 2010;11(11):1039-46. 556 16. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, 557 et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations 558 with distinct T cell-suppressive activity. Blood. 2008;111(8):4233-44. 559 17. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-560 producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of 561 activated granulocytes. Cancer research. 2009;69(4):1553-60. 562 18. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide 563 are the underlying mechanism of suppression of t-cell function in advanced cancer patients. 564 Cancer research. 2001;61(12):4756-60. 565 19. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-566 producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor 567 evasion. Cancer research. 2005;65(8):3044-8. 568 20. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, et 569 al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of 570 myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC 571 Cancer. 2010;10:464. 572 21. Oka K, Sarashina G, Yonekawa N, Watanabe O, Miyao Y, Hashimoto T, et al. G-CSF-573 producing malignant pleural mesothelioma: an autopsy case report with literature review. Int J 574 Surg Pathol. 2012;20(3):272-5. 575 22. Demetri G, Zenzie B, Rheinwald J, Griffin JD. Expression of colony-stimulating factor 576 genes by normal human mesothelial cells and human malignant mesothelioma cells lines in 577 vitro. Blood. 1989;74(3):940-6. 578 23. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived 579 suppressor cell differentiation and function. Trends Immunol. 2011;32(1):19-25. 580 24. Chee SJ, Lopez M, Mellows T, Gankande S, Moutasim KA, Harris S, et al. Evaluating the 581 effect of immune cells on the outcome of patients with mesothelioma. Br J Cancer. 2017. 582 25. Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender G. Tumor-associated 583 neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. cancer 584 Immunol Immunother. 2013;62(11):1745-56. 585 26. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism 586 regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J 587 Immunol. 2009;182(9):5693-701. 588 27. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. 589 Recommendations for myeloid-derived suppressor cell nomenclature and characterization 590 standards. Nat Commun. 2016;7:12150. 591 28. Rotondo R, Barisione G, Mastracci L, Grossi F, Orengo AM, Costa R, et al. IL-8 induces 592 exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J 593 Cancer. 2009;125(4):887-93. 594 29. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-595 associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer cell. 596 2009;16(3):183-94. 597 30. Urano N, Yano E, Evans PH. Reactive oxygen metabolites produced by the carcinogenic 598 fibrous mineral erionite. Environmental research. 1991;54(1):74-81. 599 31. Achcar Rde O, Cagle PT, Jagirdar J. Expression of activated and latent signal transducer 600 and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant 601
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
mesotheliomas: possible role for chemotherapeutic intervention. Archives of pathology & 602 laboratory medicine. 2007;131(9):1350-60. 603 32. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel 604 cytokine that activates neutrophils. The Journal of clinical investigation. 1989;84(4):1045-9. 605 33. Glynn PC, Henney E, Hall IP. The selective CXCR2 antagonist SB272844 blocks 606 interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous 607 neutrophil apoptosis. Pulmonary pharmacology & therapeutics. 2002;15(2):103-10. 608 34. Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC, Quigley JP, et al. Tumor-609 recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of 610 tumor angiogenesis and efficiency of malignant cell intravasation. The American journal of 611 pathology. 2011;179(3):1455-70. 612 35. Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE. Interleukin-8 as an 613 autocrine growth factor for human colon carcinoma cells in vitro. Cytokine. 2000;12(1):78-85. 614 36. Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS. Interleukin-8 stimulates cell 615 proliferation in non-small cell lung cancer through epidermal growth factor receptor 616 transactivation. Lung Cancer. 2007;56(1):25-33. 617 37. Takamori H, Oades ZG, Hoch OC, Burger M, Schraufstatter IU. Autocrine growth effect of 618 IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas. 2000;21(1):52-6. 619 38. Galffy G, Mohammed KA, Nasreen N, Ward MJ, Antony VB. Inhibition of interleukin-8 620 reduces human malignant pleural mesothelioma propagation in nude mouse model. Oncology 621 research. 1999;11(4):187-94. 622 39. Kasuga I, Ishizuka S, Minemura K, Utsumi K, Serizawa H, Ohyashiki K. Malignant pleural 623 mesothelioma produces functional granulocyte-colony stimulating factor. Chest. 624 2001;119(3):981-3. 625 40. Rikimaru T, Ichikawa Y, Ogawa Y, Higuchi E, Kinosita M, Oizumi K, et al. Production of 626 granulocyte colony-stimulating factor by malignant mesothelioma. Eur Respir J. 1995;8(1):183-4. 627 41. Fujiwara A, Higashiyama M, Kanou T, Okami J, Tokunaga T, Tomita Y, et al. Granulocyte-628 colony stimulating factor (G-CSF) producing malignant pleural mesothelioma: Report of a case. 629 Thoracic cancer. 2015;6(1):105-9. 630 42. Pass H, Stevens E, Oie H, Tsokos M, Abati A, Fetsch P, et al. Characteristics of nine newly 631 derived mesothelioma cell lines. Ann Thorac Surg. 1995;59(4):835-44. 632 43. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, et al. Hierarchy of 633 immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by 634 GM-CSF. European journal of immunology. 2010;40(1):22-35. 635 44. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, et al. A human 636 promyelocytic-like population is responsible for the immune suppression mediated by myeloid-637 derived suppressor cells. Blood. 2011;118(8):2254-65. 638 45. Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature 639 of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 640 2012;91(1):167-81. 641 46. Dirix LY, van Meerbeeck J, Schrijvers D, Corthouts B, Prove A, van Marck E, et al. A phase 642 II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant 643 mesothelioma. Annals of oncology : official journal of the European Society for Medical 644 Oncology. 1994;5(7):653-5. 645 47. Kosty MP, Herndon JE, 2nd, Vogelzang NJ, Kindler HL, Green MR. High-dose doxorubicin, 646 dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia 647 Group B 9631. Lung Cancer. 2001;34(2):289-95. 648
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
48. Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B. Recombinant GM-CSF plus 649 autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer. 650 2006;52(2):189-97. 651 49. Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, et al. WT1 peptide vaccinations 652 induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell 653 lung cancer. Cancer immunology, immunotherapy : CII. 2010;59(10):1467-79. 654 50. Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, Rimner A, et al. A Randomized Phase 655 II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality 656 Therapy for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2017;23(24):7483-9. 657 51. Davidson JA, Musk AW, Wood BR, Morey S, Ilton M, Yu LL, et al. Intralesional cytokine 658 therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. Journal of immunotherapy. 659 1998;21(5):389-98. 660 52. Robinson BW, Mukherjee SA, Davidson A, Morey S, Musk AW, Ramshaw I, et al. 661 Cytokine gene therapy or infusion as treatment for solid human cancer. Journal of 662 immunotherapy. 1998;21(3):211-7. 663 53. Cheung NK, Cheung IY, Kramer K, Modak S, Kuk D, Pandit-Taskar N, et al. Key role for 664 myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-665 stimulating factor for chemoresistant osteomedullary neuroblastoma. International journal of 666 cancer. 2014;135(9):2199-205. 667 54. Peters WP, Stuart A, Affronti ML, Kim CS, Coleman RE. Neutrophil migration is defective 668 during recombinant human granulocyte-macrophage colony-stimulating factor infusion after 669 autologous bone marrow transplantation in humans. Blood. 1988;72(4):1310-5. 670 55. Gargett T, Christo SN, Hercus TR, Abbas N, Singhal N, Lopez AF, et al. GM-CSF signalling 671 blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived 672 suppressor cells in vitro. Clin Transl Immunology. 2016;5(12):e119. 673 56. Cook AD, Louis C, Robinson MJ, Saleh R, Sleeman MA, Hamilton JA. Granulocyte 674 macrophage colony-stimulating factor receptor alpha expression and its targeting in antigen-675 induced arthritis and inflammation. Arthritis Res Ther. 2016;18(1):287. 676 57. Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol. 677 2016;12(1):37-48. 678 58. Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, et al. A 679 randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal 680 antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1020-30. 681
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757
Published OnlineFirst March 30, 2018.Clin Cancer Res Swati Khanna, Suzanne Graef, Francis Mussai, et al. immunosuppression in mesothelioma patientsTumour-derived GM-CSF promotes granulocyte
Updated version
10.1158/1078-0432.CCR-17-3757doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2018/03/30/1078-0432.CCR-17-3757To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158/1078-0432.CCR-17-3757